# EndoQuest Robotics

> EndoQuest Robotics develops the investigational Endoluminal Surgical (ELS) System, a flexible robotic platform that combines natural-orifice access with two-handed surgical instrumentation. Its PARADIGM trial completed enrollment in July 2026 after 50 robotic ESD procedures in 49 subjects; follow-up and data review continue, and the system is not FDA cleared or commercially available in the United States.

- **Founded:** 2017
- **Headquarters:** Houston, United States
- **Founders:** Daniel H. Kim (Founder; former company officer)
- **Products:** Endoluminal Surgical (ELS) System, EndoDrive, Flexible instruments and videoscope, Physician console and patient cart, Robotic training simulator development
- **Notable:** Best Application Award in the 2022 Surgical Robotic Challenge at the Hamlyn Symposium., FDA STeP acceptance announced January 2024., FDA IDE granted in December 2024 for the PARADIGM clinical study.

## Products & services

- **Endoluminal Surgical (ELS) System** — Investigational, physician-controlled flexible robotic platform for natural-orifice surgery; evaluated for ESD in the rectum and sigmoid colon in PARADIGM. Not FDA cleared or for commercial sale in the United States.
- **EndoDrive** — Flexible, steerable delivery system for two robotic instruments and a videoscope, with channels for insufflation, suction, irrigation, and accessories.
- **Flexible instruments and videoscope** — Two 6 mm robotic instruments with up to seven degrees of freedom, accompanied by a 3.7 mm high-definition robotic camera.
- **Physician console and patient cart** — Ergonomic hand controllers, foot pedals, heads-up display, and a mobile cart for positioning the system.
- **Robotic training simulator development** — A 2023 partnership with VirtaMed to develop skills and procedural simulation for ELS; an announced development initiative, not a verified standalone commercial product.

## Achievements

- Best Application Award in the 2022 Surgical Robotic Challenge at the Hamlyn Symposium.
- FDA STeP acceptance announced January 2024.
- FDA IDE granted in December 2024 for the PARADIGM clinical study.
- First U.S. PARADIGM procedures announced May 2025.
- PARADIGM enrollment completed July 2026: 50 procedures in 49 subjects, six investigators across five institutions.
- Company-reported preliminary results as of July 18, 2026: 100% en bloc resection, 95.8% R0 resection, 100% conversion-free, and no device-related bleeding or perforation reported to date. Follow-up, verification, and database review remained ongoing.

## Latest updates

- **2025-07** — Series D-2 financing announced; amount undisclosed in the company release.
- **2025-09** — First PARADIGM procedure at AdventHealth Orlando announced.
- **2025-10** — Planned next-generation NVIDIA IGX Thor integration announced.
- **2026-07** — PARADIGM completed enrollment; preliminary results presented at SRS 2026. Clinical follow-up and data verification continued before a planned De Novo submission.

## Links

- Website: https://endoquestrobotics.com/
- LinkedIn: https://www.linkedin.com/company/endoquest/
- Twitter/X: https://twitter.com/ENDOQUESTRobot

---

Profile page: https://yespress.io/endoquest-robotics
Published by YesPress — https://yespress.io
Last updated: 2026-10-05